Global Landscape of Benefit-Risk Considerations for Medicinal Products: Current State and Future Directions.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pharmaceutical Medicine Pub Date : 2022-08-01 Epub Date: 2022-07-03 DOI:10.1007/s40290-022-00435-x
Max Waschbusch, Lisa Rodriguez, Andreas Brueckner, Kerry Jo Lee, Xuefeng Li, Oksana Mokliatchouk, Lothar Tremmel, Shuai S Yuan
{"title":"Global Landscape of Benefit-Risk Considerations for Medicinal Products: Current State and Future Directions.","authors":"Max Waschbusch,&nbsp;Lisa Rodriguez,&nbsp;Andreas Brueckner,&nbsp;Kerry Jo Lee,&nbsp;Xuefeng Li,&nbsp;Oksana Mokliatchouk,&nbsp;Lothar Tremmel,&nbsp;Shuai S Yuan","doi":"10.1007/s40290-022-00435-x","DOIUrl":null,"url":null,"abstract":"<p><p>In the last decade there has been a significant increase in the literature discussing the use of benefit-risk methods in medical product (including devices) development. Government agencies, medical product industry groups, academia, and collaborative consortia have extensively discussed the advantages of structured benefit-risk assessments. However, the abundance of information has not resulted in a consistent way to utilize these findings in medical product development. Guidelines and papers on methods, even though well structured, have not led to a firm consensus on a clear and consistent approach. This paper summarizes the global landscape of benefit-risk considerations for product- or program-level decisions from available literature and regulatory guidance, providing the perspectives of three stakeholder groups-regulators, collaborative groups and consortia, and patients. The paper identifies key themes, potential impact on benefit-risk assessments, and significant future trends.</p>","PeriodicalId":19778,"journal":{"name":"Pharmaceutical Medicine","volume":"36 4","pages":"201-213"},"PeriodicalIF":3.1000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40290-022-00435-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

In the last decade there has been a significant increase in the literature discussing the use of benefit-risk methods in medical product (including devices) development. Government agencies, medical product industry groups, academia, and collaborative consortia have extensively discussed the advantages of structured benefit-risk assessments. However, the abundance of information has not resulted in a consistent way to utilize these findings in medical product development. Guidelines and papers on methods, even though well structured, have not led to a firm consensus on a clear and consistent approach. This paper summarizes the global landscape of benefit-risk considerations for product- or program-level decisions from available literature and regulatory guidance, providing the perspectives of three stakeholder groups-regulators, collaborative groups and consortia, and patients. The paper identifies key themes, potential impact on benefit-risk assessments, and significant future trends.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
医药产品利益风险考量的全球格局:现状和未来方向。
在过去十年中,讨论在医疗产品(包括器械)开发中使用利益-风险方法的文献显著增加。政府机构、医疗产品行业团体、学术界和合作联盟广泛讨论了结构化收益-风险评估的优势。然而,丰富的信息并没有导致在医疗产品开发中使用这些发现的一致方式。关于方法的指导方针和文件虽然结构良好,但并没有就明确和一致的办法达成坚定的协商一致意见。本文从现有文献和监管指导中总结了产品或项目层面决策的利益风险考虑的全球格局,并提供了三个利益相关者群体——监管机构、合作团体和财团以及患者的观点。该文件确定了关键主题,对利益风险评估的潜在影响,以及重要的未来趋势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmaceutical Medicine
Pharmaceutical Medicine PHARMACOLOGY & PHARMACY-
CiteScore
5.10
自引率
4.00%
发文量
36
期刊介绍: Pharmaceutical Medicine is a specialist discipline concerned with medical aspects of the discovery, development, evaluation, registration, regulation, monitoring, marketing, distribution and pricing of medicines, drug-device and drug-diagnostic combinations. The Journal disseminates information to support the community of professionals working in these highly inter-related functions. Key areas include translational medicine, clinical trial design, pharmacovigilance, clinical toxicology, drug regulation, clinical pharmacology, biostatistics and pharmacoeconomics. The Journal includes:Overviews of contentious or emerging issues.Comprehensive narrative reviews that provide an authoritative source of information on topical issues.Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by PRISMA statement.Original research articles reporting the results of well-designed studies with a strong link to wider areas of clinical research.Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pharmaceutical Medicine may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
期刊最新文献
European Pharmaceutical Industry Medical Information: A Role to Play in the Provision of Medicine-Related Information to Patients. Addressing Challenges in Antibiotic Access: Barriers, Implications and Strategies for Solution. Transdermal Drug Delivery Systems: Different Generations and Dermatokinetic Assessment of Drug Concentration in Skin. The Pharmaceutical Year that was, 2024. Cultivating Excellence: Future-Proofing Medical Affairs with Tailored Talent Programs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1